With virtually bent knees and proper posture, Soter Analytics Pty Ltd. raised $12 million in a series A funding round to build on its artificial intelligence (AI)-based ergonomic wearables line that helps workers minimize injuries on the job. The technology tracks all significant shoulder and back movements and provides personalized real-time feedback before improper lifts or twists land users on their backs or in rehab.
Just two weeks after winning U.S. FDA approval for the first orally dissolving formulation of dexmedetomidine for agitation in schizophrenia and bipolar disorders, Bioxcel Therapeutics Inc. has secured commitments for up to $260 million to support the product’s commercial launch, slated for this quarter in addition to a planned European marketing application.
Biopharmas raising money in public or private financings, including: Affimed, Biotech Group Acquisition, Crinetics, Foresite Life Sciences, Microviable, Pepgen, Okyo, Oncoquest, Quest, Sionna, Tessera, Trevena.
Cairdac SAS closed its first funding round, raising nearly $18.5 million to increase development of an autonomous, leadless pacemaker transcatheter system (ALPS) powered entirely using kinetic energy from the heart. Five French private equity funds and banks participated in this series A round.
Lyra Therapeutics Inc.’s $100.5 million private placement has investors moving to the tune of the ear, nose and throat specialty therapeutics company. Lyra’s stock (NASDAQ:LYRA) jumped from early April trading in the $4.20 range to $6.02 with the announcement April 8 of the pending placement. The stock shot up again on April 13 when the placement finalized and surged in after-hours trading, ultimately spiking over $7 shortly after the opening bell April 14.